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Abstract
Serum amyloid A (SAA) is the most prominent acute-phase protein in vertebrates and its 
role in innate immunity has been reviewed. SAA functions are located on special regions 
of SAA, which are highly conserved in all vertebrates. 1. The discovery of the acute-phase 
nature of SAA before its existence was known by experimental murine AA amyloidosis 
induced by septic conditions. 2. Identification of the amyloid substance and its precursor. 
3. SAA changes its conformation and antigenic presentation when it is separated from 
HDL during the acute phase. Febrile temperatures activate SAA through the separation 
from HDL. There is a temperature-specific gradual separation of SAA isotypes or groups 
of isotypes from HDL. 4. Generic monoclonal AA antibodies mc4 and mc29 assist in elu-
cidating selected SAAs’ vital functions (as in defense, platelet functions, female propaga-
tion and others). 5. In a murine sepsis model, the monoclonals mc4 and mc29 can cause 
early death while the intact SAA can prevent this. Through this, a checkpoint (“stop and 
go”) for survival was discovered. Generic monoclonals can also identify the life-saving 
structures of SAA’s vital functions and those of other acute-phase proteins. This principle 
is essential for the production of novel drugs against sepsis and other innate-related dis-
eases. 6. Some remarks follow.
Keywords: amyloidosis, serum amyloid A (SAA), febrile temperatures, inflammations, 
sepsis, invariant checkpoints, generic monoclonal antibodies, innate immunity, 
therapeutic options
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1. The acute-phase nature of an enigmatic amyloid precursor in early 
experiments
1.1. Microscopic morphologic evidence
The task of my earliest work in pathology was to find out whether there was a soluble serum 
precursor for amyloidosis (This spacious scientific field has been reviewed pain part recently) 
[1, 2]. In experimental murine amyloidosis induced by septic conditions [3], morphologically 
significant signs are visible in Figure 1 showing large amounts of hepatic amyloid (white 
areas), now recognized as amyloid A (AA). This amyloid was first deposited at the sites where 
the blood stream entered from the triangle of Glisson into the liver capillaries. The entire 
branches of blood vessels entering the liver parenchyma (left large vessel) are decorated with 
amyloid and, on the other hand, the branches that allow the blood to leave the liver are devoid 
of amyloid (right large vessel). This implies that the amyloidogenic protein is being deposited 
immediately when it reaches the liver upon assumed changing conditions (still unknown) 
by which amyloid is deposited from a soluble precursor. With time, the deposits grow by 
Figure 1. Photomicrograph of murine AA amyloidosis. Tissue section showing hepatic capillary amyloid deposits (white 
areas) induced by septic multi-microbial exposure after 25 days. The amyloid is deposited under pressure visible as 
the rough liver surface (at the top), which is usually sleek. Formalin-fixation, 4–6 μm paraffin section, HE-staining, 
magnification 24.1× [4].
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apposition toward the central liver vein (darker areas) until most of the liver is transformed 
into amyloid in a fatal amyloidosis. This behavior requires a consistent, steady and very fast 
transformation of an assumed precursor to amyloid by entering the liver capillaries. The amy-
loid is deposited under pressure and visible as the rough liver surface (at the top), which is 
usually sleek.
1.2. Relative parabiotic barrier
When the assumed precursor is present in blood, as suggested by morphologic evidence, it 
should cross the anastomosis between artificial Siamese twins (parabiosis) with one partner 
induced to develop amyloidosis through septic conditions. However, this transmission does not 
always occur. The septic partner developed amyloid in 92.5% of pairs and the untreated partner 
in only 13.4%, and the latter was statistically not different to that seen in control pairs without 
any treatment [4]. The failure of crossing the anastomosis was excluded by 51Cr-tagged erythro-
cytes [5]. Since the anastomosis was fully permeable, this type of parabiotic barrier was not an 
absolute one but a relative one caused by a short half-life of the agent that was removed from the 
bloodstream before it could cross the permeable anastomosis. The results of quantitation of the 
blood flow by 51Cr erythrocytes, including a mathematical model of the exchange rate, shows 
that half of the blood was exchanged between the partners in 22.3 min. Therefore, a short half-
life far below 22.3 min indicates a protein with a rapid clearance in minutes or even seconds, a 
property that is addressed today as an acute-phase nature, but still enigmatic precursor [5].
1.3. The clearance of SAA reported by other groups
The half-life of SAA1 and SAA2 in plasma of normal mice was reported for SAA-HDL as a 
T1/2 of 75–80 min and both isotypes were similar. However, when trace amounts of SAA were 
given, they were rapidly cleared [6]. Another report measured the clearance of the complex 
SAA-HDL for SAA1 T1/2 of 75 min and SAA2 T1/2 of 30 min, respectively. The clearance 
was delayed when both isotypes were bound to high-density lipoprotein (HDL) [7]. Both 
reports did not measure SAA under acute-phase conditions (APC). However, the report of 
Hoffman and Benditt [6] found a rapid clearance with trace amounts of SAA devoid of HDL 
and confirmed our data that are performed under a septic acute-phase condition that was to 
be observed when SAA was separated from HDL (see below).
2. Identification of the amyloid substance and isolation of its serum 
precursor
Amyloids of different clinical settings (also in animals, see Figure 1) represent characteristic 
fibrils under electron microscopy [8]. Therefore, for chemical identification of the amyloid, 
these fibrils had to be extracted in pure form followed by chromatographic isolation of the 
major amyloid protein for its chemical analysis by amino acid sequence analysis. The method 
of isolation of the pure amyloid fibrils was pioneered by Pras et al. [9]. The first amino acid 
sequence of an amyloid protein was published by Glenner et al. [10], which was derived from 
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a monoclonal immunoglobulin κ-light chain and was named ALκ. The first sequence identify-
ing the chemical nature of inflammation-induced amyloid in monkey and human amyloid 
was published by Benditt et al. [11], which was named amyloid A (AA). The first anti-AA 
antibodies were prepared in rabbits where a serum protein in patients suffering from inflam-
mations was detected immunochemically. This protein had an α
1
-electrophoretic mobility 
and was in serum approximately 180 KDa by calibrated gel filtration [12] and thus ready to 
monitor the isolation of the soluble with anti-AA reactive precursor. This isolation of serum 
protein began in summer 1972 and was monitored with another rabbit anti-AA antibody. 
Its chromatographic separation from serum yielded a native 200 ± 20 kDa AA reactive pro-
tein, which was further chromatographically isolated in 5 M guanidine-HCl. The AA reactive 
protein had an α
2
-electrophoretic mobility and a molecular size of 12.5 kDa. Since this new 
protein had the same N-terminal amino acid sequence as AA, it was named serum amyloid A 
(SAA) [13]. Since SAA was larger than AA, a limited proteolytic cleavage had to be presumed 
in order for the former to generate AA. During the isolation of SAA and its purification to one 
size by gel filtration, by isoelectric focusing, however, eight SAA bands of different isoelectric 
point named A-H were identified with anti-AA antibodies (with AAE as the major SAA spe-
cies for the planned radioimmunoassay), thus indicating the first signs of a polymorphism of 
SAA [13]. In addition, in plasma, SAA is bound to HDL [14].
3. SAA-HDL and febrile temperatures
3.1. Temperature-induced structural changes of SAA in serum
When examining a patient’s acute-phase serum (APS) with elevated SAA in immunodiffu-
sion (ID) at different temperatures and different times using a polyclonal AA antiserum in 
comparison with isolated control AA, this resulted in the three different precipitation patterns 
presented in Figure 2. In (a), one recognizes a line of identity of AA with all four patients’ 
sera as if the SAA (probably SAA1 and SAA2) reaction were done with pure SAA. At 4°C 
in (b), however, there is no reaction with SAA-HDL in serum. This is due to the hiding of 
the AA-reactive parts of SAA through HDL. However, when the temperature was switched 
to room temperature after the reaction in (b) at 4°C the SAA containing serum resulted in a 
strong line after releasing the SAA from HDL in (c) as seen in (a). However, different from 
the pattern in (a), the precipitation line of AA-anti-AA is somewhat independent of the SAA-
anti-AA line, thus indicating that the homologous AA-anti-AA line seems to be more stable 
than the SAA-anti-AA line. These results show that SAA-HDL is stable in full APS at 4°C 
where the AA-reactive sites are covered by HDL. When at room temperature (in ID buffer), 
where SAA is released from HDL and is now accessible to antibodies for precipitation, it is 
reactive. Therefore, the separation of SAA from HDL is temperature dependent [15]. These 
results became only fully explainable through Section 3.2, where the separation of SAA from 
HDL became clear [14].
In addition, we prepared recombinant SAA2 and, when added to normal human serum, it 
was possible to repeat exactly that behavior reported in Figure 2. This shows that SAA alone 
can reproduce this phenomenon [16].
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3.2. The molecular size of the SAA and SAA-HDL at different febrile temperatures
Temperature-dependent molecular weight determination of AA-antigenic proteins of acute-
phase serum (APS) has been performed using an ACA-34 gel filtration column in PBS with the 
enzyme inhibitor phenylmethylsulfonylfloride (PMSF) under various temperatures as shown 
in Figure 3. The size grading was done by the serum proteins IgM, IgG, albumin and, in addi-
tion, cytochrome C and the salt marker N-ε-DNP-lysine. The proteins were identified by way of 
the size position in the column by immunodiffusion as SAA-HDL at a size of ca. 180–200 kDa 
or SAA at 12.5 kDa. The different temperatures were kept with a temperature-controlled glass 
jacket, that is at 37°C in column run A, at 38°C in B, at 40°C in C and at 42°C in D. E was run 
as D, but without enzyme protection by PMSF, thus showing some degradation of SAA [18].
At a normal body temperature of 37°C, AA-containing proteins are at a single position as that 
of the SAA-HDL stable complex in A (fractions 34–37). However, already at 38°C, the stable 
complex SAA-HDL begins to dissociate as shown in Figure 3, run B. AA antigenic proteins 
appear at three positions, that is first of all at the void volume at fractions 19–20 (which has not 
been further analyzed, but could be related to aggregated SAA and/or its derivatives), secondly 
at the position of the stable SAA-HDL complex at fractions 34–36 and thirdly at the position of 
the HDL-free SAA at 53–56, as determined by the antigenic differentiation as seen in Figure 2. 
This size differentiation may also indicate functional heterogeneity, as the different affinities 
of SAA to HDL. This dissociation begins at 38°C and progresses with diminution of the SAA-
HDL complex until run C. SAA-HDL disappeared at a “threshold of life” in run D at 42°C and 
above where the SAA species was maximized and the broadest was seen at fraction 53–56. This 
shows a temperature-induced gradual dissociation of SAA from HDL at the different febrile 
temperatures, which was shown here in vitro. This may also occur under systemic and local, 
acute-phase conditions, with the release of different SAA isotypes at different temperatures, for 
functions to be discovered. Finally, the SAA monomers released at different temperatures differ 
Figure 2. Immunochemical comparison of SAA-HDL, SAA and AA. Immunodiffusion (ID) at different temperatures [14, 
15]. The ID was performed in 1.5% Seakem agarose in 0.03 M barbital buffer, pH 8.6 with the same reagents in each of 
the three plates à 6 wells ((a)-(c)). Top and bottom well contained AA (0.1 mg/ml), the middle well contained polyclonal 
rabbit anti-AA antibodies undiluted and the 4 side wells contained elevated SAA-HDL containing APS from 4 patients 
at 1/10 diluted. Plate (a) after diffusion over night at room temperature, plate (b) at 4°C over night and plate (c) first at 
4°C over night as plate B at 4°C followed by room temperature for 6 h similar to plate (a).
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in size. SAA in B is somewhat smaller than SAA in C. In addition, both appear at 42°C in D 
together as a broad combination of the two SAAs in B and D. In conclusion, SAA separated from 
HDL at 38°C in B has a lower affinity to HDL and is smaller, and SAA with a higher affinity for 
HDL is larger. Different isotypes and sizes of SAA are known [1, 2, 13]. The acute-phase SAAs, 
aSAA1 and aSAA2, are each 12.5 kDa with 104 amino acids and the constitutive SAA (cSAA), 
which is 14 kDa and has 112 amino acids. Since SAA1 has the lowest affinity for HDL and is 
the most amyloidogenic SAA, it could have separated from HDL in run at 38°C in B already, 
while SAA4, which is somewhat larger than the aSAAs, could be a component in the C. These 
indications can be solidified using isoelectric focusing or SAA-isotype-specific antibodies [1, 2].
3.3. Gradual dissociation of SAA-HDL during a continuous temperature gradient
While these experiments above were done stepwise, one by one, a more precise dissociation 
of the SAA-HDL separation was performed by electrophoresis in 1.5% agarose across a con-
tinuous temperature gradient in a single flat gel, as shown in Figure 4. The two sides between 
the agarose gel were kept at a constant temperature of 15°C in T1 and of 65°C in T2 [17].
The results in Figure 4 show two horizontal bands of samples of one patient in the form of 
dots across the temperature gradient. The SAA-HDL band of α
1
-electrophoretic mobility is 
marginally stained due to the concealing of the AA-antigenic determinants of SAA within 
Figure 3. Size separation of SAA-HDL at febrile temperatures. SAA-HDL in a patient’s acute-phase serum with a 
common cold was separated in A at 37°C, B at 38°C, C at 40°C and D at 42°C by gel filtration. All individual fractions 
(20–70) were examined and semi-quantified by ID using polyclonal rabbit anti-AA antibodies [15, 17].
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the SAA-HDL complex at low temperatures. The hiding of the antigenic determinants dis-
appeared gradually from 38°C (the 5th sample) until it is completely above 42°C with the 
appearance of large amounts of SAA (intensive staining of the band with α
2
-mobility). By 
gradually increasing the temperature, the SAA release increases gradually while the SAA-
HDL fades away up to the extreme exposure at 42°C and beyond, in agreement with the 
stepwise separation of SAA from HDL shown in Figure 3. Also important during this grad-
ual temperature-induced separation from HDL seems to be that the morphology of the dots 
is different. They changed by their shape in the longitudinal direction, which is consistent 
with the fact that SAA is not uniform and consists of a group of homologous, but chemically 
different, SAAs demonstrating different isoelectric points (13 reviewed by [1, 2]). Another 
observation concerns the AA-antigenic species below 37°C in the first four samples. These 
slow, arc-like uniform samples could represent an SAA species, which is always active as a 
monomer regardless of temperature. This species seems to be less acidic. It could be a type of 
SAA species for the general protection under normal condition. In sample 5, this “arc SAA” 
is overlaid by a more acidic SAA released from the acute-phase proteins (APPs) SAA1 or 
SAA2, thus changing the spots to a more longitudinal pattern. With increasing temperature, 
the SAA spots become thicker and increase more in the longitudinal direction. This “arc 
SAA” needs to be analyzed since it does not seem to be part of the intact SAA-HDL complex 
(we did not check for SAA4). Finally, far above a temperature of 42°C, the SAA species seems 
to be stable. Parallel to the gradual release of SAA, at the same time, the SAA-HDL complex 
while losing SAA is gaining more negative charges with increased temperatures. Moreover, 
the trailing of SAA in samples 5–8 possibly indicates the gradual separation of differently 
charged SAA species.
Figure 4. Electrophoresis of SAA-HDL across a continuous temperature gradient in agarose [18]. An APS was applied 
(see horizontal arrow) in 13 identical samples containing SAA-HDL across a temperature gradient. The small cross-
hatched bar on the cm ruler denotes 37°C at the left margin and 42°C at the right one. Electrophoresis was done in 1.5% 
agarose (Seakem ME) in 25 mm barbital buffer, pH 8.6 followed by a standard Western blot developed with a mixture 
of the monoclonal anti-AA antibodies [19] mc1 + mc4 + mc29 at 1 + 1 + 1, 1/100 (see Table 1). One recognizes SAA-HDL 
at the left-side site marking the α
1
-electrophoretic mobility (upper band). This band fades beginning from 38°C to 42°C, 
while the SAA freed from HDL (as in Figure 3) starts to appear at 38°C at the α
2
-electrophoretic mobility with the 
very strong exposure of formerly concealed antigenic AA determinants detected after the strongest exposure appears at 
febrile temperatures between 38°C and 42°C (see cross-hatched bar). See vertical arrow at 42°C- 43°C.
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3.4. Activation of the SAA by separation from HDL under febrile temperatures and 
consequences
Taken together [15, 17, 18, 21], it is clear that the mechanism of separation of SAA from HDL 
in vitro is also strictly regulated in vivo by body temperatures above 37°C. Therefore, this is a 
key mechanism that can be induced and activated basically by two different manifestations. 
The most common is the orthologic APR activation [33] of SAA. This occurs with a maximal 
SAA concentration of up to 1000 times within a day as a systemic “biochemical thunderstorm” 
with a myriad of activating and inhibiting events simultaneously, which are not understood 
in detail today [1, 2]. During these events, the cause of the APR will be eradicated and the APR 
becomes curative. With this beneficial outcome, the normal immune homeostasis returns in a 
foreseeable future. However, when the APR cannot overcome its initial cause, it will become 
a pathologic APR [33] with a “persistent biochemical thunderstorm” and lacking a self-driven 
cure. The consequences can be summarized in an exhaustion of the resources of the organ-
ism and decline of the metabolic activity through a multitude of clinically challenging condi-
tions exemplified by severe viral and bacterial chronic inflammations, systemic inflammatory 
response syndrome (SIRS) or uncontrolled chronic infections, sepsis and septic shock [1, 2]. 
Moreover, when the infection remains limited, a local APR will take care of it.
The functions of the four human isotypes, SAA1, SAA2, (SAA3 in humans is only transcribed in 
some cells) and SAA4 have not been fully analyzed. They have arisen through gene duplications, 
thus indicating important individual functions either alone or in combination. As described 
before, the human acute-phase A-SAA has two very similar isotypes, A-SAA1 and A-SAA2, in 
the APR mostly synthesized in the liver and expressed in most body cells (see below) and the 
constitutive C-SAA4 and some allotypes in SAA1 and SAA2. For a review of the SAA heteroge-
neity and its known functions, see the reviews [1, 2].
Another discovery was the discontinuous separation of SAA from HDL described above at 
different temperatures, meaning that not all SAA molecules are being separated from HDL at 
a single temperature except for the temperature of 42°C (Figures 3 and 4). In fact, these figures 
show that the separation of SAA is spreading out over the whole febrile temperature range 
starting from 38°C to 42°C and above. In addition, based on these observations in Figure 4, it is 
possible that SAA isotypes and allotypes are separated from HDL at different febrile tempera-
tures and thereafter fulfill their different functions locally or systematically as individual SAA 
species as is also to be derived from Figure 3. Another indication for the differential release 
of the SAA species can be detected in Figure 4 in the different shapes of the protein blots of 
the SAAs devoid of HDL, thus indicating possible SAAs with distinct isoelectric points (IP). 
In Figure 4, there are free dots before 37°C named (for convenience) “arc SAA,” the least 
acidic SAA. The SAA species released from HDL after 37°C (“38 SAA”) are probably the more 
acidic ones. In this sense, the dot changes also occur later on 39°C-, 40°C-released SAA, etc. 
Analyzing the spots for the identity of the various SAA species could show whether these 
indications did discover a mechanism by which the different SAA species can be released 
from HDL and thereby are being activated at specific temperatures alone or with other SAAs 
for special purposes, which need to be analyzed. These points may also be of therapeutical 
interest. This proposed temperature selection of SAA isotypes could specify the needed APR 
function for a specific purpose. The increase of the organism’s temperature is being induced 
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by the organism as a response to various stimuli, exemplified by bacterial invasion. It could 
represent some sort of a “gear shift” for providing a graded response in order to release spe-
cial SAAs to provide adequate amounts, which are necessary “tools” for survival. This could 
occur in concert with other agents including other APPs and cytokines of the APR network. 
The possible therapeutical manipulation of the body’s temperature (“the gear shift”) in vivo 
needs the precise analysis of this phenomenon in vivo first.
4. Application of antibodies
4.1. Polyclonal and monoclonal antibodies prepared against AA and SAA
In a collaborative study, each of the eight species-specific polyclonal AA antibodies against 
eight species (including humans) was immunohistochemically tested against the AA amy-
loids of eleven different species, including those of humans. The results showed a strong 
reactivity only with the homologous species and with only some cross-reaction with a related 
species. The reactivity was in general species specific, but a universal generic AA antibody 
could not be obtained in these eight polyclonal antibodies [37].
The next step was to produce murine monoclonal antibodies against AA and SAA [20]. Their 
value and merit have been documented by the inventors Köhler and Milstein [38]. Monoclonal 
antibodies are represented by one amino acid sequence and have the value of a chemical 
reagent. We selected 20 stable clones (see Table 1), which were epitope mapped [31] and 
immunohistochemically tested on AA amyloids in 10 different mammals, many humans and 
9 different birds. Some cross-reactivity with some monoclonals was detected. Most of the 19 
AA amyloids tested could be identified with the two monoclonals mc4 and mc29, showing 
that most of these AA amyloids have some peptides in common and these antibodies recog-
nize the same or very similar epitopes of AA in different species. In addition, antibodies of 
all clones were tested for binding with 15 synthetic SAA peptides in only 4 clones the epitope 
could be identified. These included the known clones mc4 and mc29 (see above), and the two 
new ones, mc1 and mc20 (see Table 1). In APS, two different charge variants of SAA have 
been detected with these monoclonals [22].
The cause of the failing reactivity of most of the synthetic peptides with most of the monoclo-
nals may be due to the presence of more discontinuous epitopes. This could also be deduced 
from the fact that SAA shows multiple short peptides that alternate between the invariable 
(red) and the variable (white) peptides, as shown in Figure 5 (see also below).
Moreover, since mc21 was negative with the linear peptides, but reacted very strongly with AA 
amyloid in tissues, it was epitope mapped differently. It was mapped with endoproteinase Asp-
N-generated peptides from a pure and partially amino acid-sequenced human AA (KIR) protein 
of 8.4 kDa. Of the 11 distinct peptides separated by RP-HPLC, mc21 reacted only with a single 
peptide, which was aa 33–42 of SAA [32]. This peptide is almost identical with the largest invariant 
peptide of SAA (see Figure 5). Two other monoclonals mc9 and mc13 did not  show any reaction 
with these 11 distinct HPLC peaks [32] although they were reactive with AA in tissue sections. 
Here again, in linear SAA peptides, the discontinuous epitopes of SAA may not be preserved.
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Therefore, another strategy for the epitope mapping has been worked out that is the cooperative 
precipitation with either the antigens AA or SAA in 1.5% agarose gel. Applied were various 
combinations of two different monoclonals on one antigen, respectively. A precipitation showed 
that the two given monoclonals react with two epitopes. This approach resulted in precipitations 
and the epitope could be estimated roughly in some of the antibodies (unpublished). This has 
been expected since all the AA/SAA antibodies were selected by reactivity with amyloid in tis-
sues. Finally, precipitation with SAA but not with AA pointed to a monoclonal against the SL 
peptide (see Figure 5, aa 77–104). Similarly, SAA isotype-specific monoclonals could have been 
selected by a similar approach.
For 
notes
Clone no Internal lab 
K-Nr.
Isotype Quality References (selected)
Epitope and SAA 
peptides
Usage 
IHC
Usage EM
mc 1* 17 IgG 2a κ 5–16
7–15
+++ +++ [17, 20–28]
mc 2 ++ [22]
mc 3 33 +
mc 4 34 IgG 1 κ 19–31 +++ +++ [17, 20–25, 29, 30]
mc 8 38, 57 IgG 3 κ 25–76 ++ 0 [20, 22, 25]
mc 9 39, 41, 53 IgG 1 κ +++ 0 [20, 22, 25, 31]
mc 12 40, 42 IgG 2b κ 25–76 ++ 0 [20, 22, 25, 31]
mc 13 43, 54 IgG 1 κ +++ ++ [20, 22, 24, 25]
mc 15 45 +
mc 17 47 +
mc 20 50, 28
60
IgG 2a κ 60–75
25–76
++ +++ [17, 20–22, 25, 31]
mc 21 65 IgG 1 κ 33-42 +++ [32]
mc 22 70 IgG 2b κ + 0 [25]
mc 23 63 IgG 1 κ +
mc 25 55, 124, 125, 126 ++
mc 27 77, 127 IgM κ ++
mc 28 58, 128 +++ +
mc 29 129 IgG 1 κ 28–40
25–76
+++ +++ [17, 21, 24–31, 33–36]
mc 30 130 IgG 1 κ +++
mc 31 131 IgG 1 κ + 0 [25]
Explanations: IHC, immunohistochemistry; EM, immunoelectron histochemistry.*Available from Dako, Denmark.
Table 1. Monoclonal AA and SAA antibodies [20].
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4.2. Identification of functional SAA epitopes by the monoclonals: finding their use 
and detecting their function
4.2.1. Diagnostic application
Monoclonals (see Table 1) are being applied for classification of AA amyloid in tissue sections 
when a recent amyloidosis was diagnosed in a patient or in an animal. Every amyloid has to 
be classified for therapeutic and prognostic purposes. This is exemplified in exploiting the 
generic monoclonals mc4 and mc29 (in Refs. [23, 24]) by either the immunohistochemical 
classification (IHC) on paraffin section of animal AA amyloidosis [23, 24] or by the immu-
noelectron microscopic classification (EM) of human AA amyloid on ultrathin sections [25].
4.2.2. The structure of SAA
The SAA1 and SAA2 proteins are presented in Figure 5 as a continuous string with 1–104 
amino acids. SAA consists of two parts, the N-terminal AA 1–76 polypeptide, which causes 
AA amyloidosis in humans [11] and animals under unfavorable inflammatory conditions 
[23, 24], and the C-terminal SL 77–104 polypeptide, whose function is stabilizing the two 
double coils [39, 40]. Figure 5 was constructed using data from the USCS Genome Browser 
(GRCH38hg38) Assembly, as reported by 2.
The structure of SAA consists of four α-helical coils, 1–4, with 1–27, 32–47, 50–69 and 73–88 
aa in length, respectively, followed by a tail after the 4th coil. These four coils are arranged 
in two antiparallel double coils, whereby 1 joins 3 and 2 joins 4 [39]. Each α-helix and its 
tail contain alternating blocks of twenty invariable peptides (Figure 5, in red, numbered 
1–20). The variable peptides that can be species specific are the white, unstained sites in 
between the invariable peptides. Variables are also the peptides joining the coils, which 
Figure 5. Structure of SAA and epitope-mapped AA monoclonal antibodies. The structure of SAA 1–104 and its 
fragments AA 1-76 and SL-77-104 with invariant (in red) and variant (white in between the red) peptides and epitope 
mapped of five monoclonal AA/SAA antibodies. There are three species-independent (mc4, mc21 and mc29), and two 
variant as well as species-specific (mc1 and mc20) monoclonal antibodies against AA and SAA. The positions of epitopes 
on the α-helical coils 1–4 and the contribution of the invariable (red) and variable peptides are also visible.
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represent the turns. In addition, the tail is winding around these double coils for stabiliza-
tion [39, 40]. This conformation of SAA with the short-distance, alternating peptides in red 
and white would need more exact three-dimensional analyses for identifying the proposed 
discontinuities of peptides based on the partial un-reactivity of the monoclonals with linear 
peptides (see above).
4.2.3. The invariant peptide clusters of SAA and the binding sites of the SAA monoclonal 
antibodies
The monoclonal antibodies can be divided into three categories by the kind of epitope onto 
which they bind. In (a), they bind to species-specific epitopes and could perhaps also be 
detected with polyclonal antibodies [37]; in (b), they bind to AA amyloid in tissue section, but 
not to synthetic linear peptides, and are probably reacting with discontinuous epitopes of the 
SAA, and in (c), they bind to species independent, i.e., the invariant peptides and epitopes of 
AA and SAA, which are almost identical throughout the vertebrates (reviewed in [1, 2]). These 
special antibodies can also be called “generic” AA/SAA antibodies. Generic SAA antibodies 
are mc4, mc21 and mc29 (the latter contains also an additional specificity; see later). The two 
monoclonals that functionally bind to variable epitopes are mc1 and mc20 and belong to a 
category in (a). All monoclonals and their known binding synthetic peptides are listed in 
Table 1, together with their binding to patients’ and animals’ AA amyloid in formalin-fixed 
paraffin tissue sections [20, 23, 24] and ultrathin sections for EM [25].
The binding sites of the monoclonals to SAA are shown in Figure 5. The invariant parts of 
SAA contain ancient peptide clusters preserved during their evolution from the lampreys 
(over 500 Mio years without hardly any changes, Wikipedia) to the mammals, including 
humans. Again, we as humans have the invariable peptides of SAA in common with all verte-
brates and the lamprey. Therefore, these special peptides have to be of utmost importance for 
mechanisms related to the proteostasis of many systems. They become extremely activated 
when in imbalance, exemplified by injuries and inflammation or bacterial infection, and in the 
event that their activation cannot be resolved. This can result in a sepsis. Thus, one can assume 
with some likelihood that a single amino acid exchange in these 19 invariant areas must not 
have been accepted throughout evolution. Indications are in the literature that natural SAA 
behaves differently as compared to recombinant SAA or SAA with a single amino acid change 
or exchange [1, 2]. The importance of the proteins of the SAA family for survival can therefore 
hardly be overestimated and the phrase that SAA is “the hub in the interaction network” [40] 
can express this eminent role of the SAA.
4.2.4. Properties of the individual monoclonals against AA presented here
4.2.4.1. mc1
This monoclonal antibody mc1 (see Table 1 and Figure 5) is of interest since it binds to the 
most N-terminally positioned human-specific epitope on SAA (aa 5–16), but only when it 
is devoid of HDL. Thus, SAA can be distinguished from SAA-HDL through the failure of 
mc1 to bind to the complex of SAA-HDL, since HLD conceals the mc1 epitope of SAA [15]. 
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Recombinant SAA shows the same binding to HDL and the same temperature release of 
SAA from HDL in vitro [21]. When separated from HDL under febrile temperatures, it can 
rebind again to HDL at body (or lower) temperatures. The binding is therefore reversible 
except when the temperature is above 41°C for some time, when it probably aggregates 
irreversibly [34]. The temperature-dependent mechanism has been proposed for activating 
the SAAs (see Figures 2–4). When fever is systemic, the free SAA load is part of the systemic 
APR. When local febrile temperatures are induced by local injuries or infection, a local 
APR is induced with local SAA. This can also apply for local tumors (see below). How this 
acts is not fully known. Where is the mc1 epitope located, considering that three invariant 
peptides are located within the 5–16 peptide stretch? Since the specificity is human specific, 
these peptides should be among the 2–3 variant areas; those are probably the white areas of 
the 5–16 peptide stretch; see Figure 5. In addition, this mc1 epitope (aa 5–16) has an overlap 
of 7 [5–11] of the 11 aa residues with the presumptive lipid-binding site (aa 1–11) (estab-
lished by Turnell et al. [41]). Finally, mc1 binds very reliably to human (and some primate) 
AA in fixed paraffin sections and in ultrathin sections for EM [25], and not to SAA-HDL in 
serum at lower body temperatures (see above). Therefore, this murine monoclonal anti-AA 
mc1 has become a standard for examining human AA and SAA (available from Dako).
4.2.4.2. mc20
In tissue sections, this monoclonal (see Table 1 and Figure 5) reliably binds to human AA 
amyloid and is being used for diagnostic purposes. It binds to the synthetic peptide aa 60–75 
of SAA, which is located at the longest variable peptide stretch of SAA and located at the 
C-terminal half of the third α-helical coil, and, to a minor extent, at the small N-terminal part 
of the fourth coil, which contains the first invariable peptide no. 12. We do not know whether 
this mini peptide is part of the mc20 paratope.
4.2.4.3. mc4, mc21 and mc29
These antibodies demonstrated immunohistochemical, species-independent binding to most 
AA-type amyloids of the vertebrates (see above). They were therefore directed against the 
invariant peptides of SAA, which are located on the first and second α-helical coils. Their 
extent and their differences are depicted in Figure 5. The clone mc4 reacts largely with the 
invariant peptide no. 4–6 on coil 1. This clone binds differently as compared to mc21 and mc29, 
both of which bind to the 7th peptide of coil 2, the largest invariant peptide of SAA. While 
mc21 seems to be only reacting with peptide no. 7, the monoclonal mc29 extends to the vari-
ant joining peptide area (aa 28–32) that is between coil 1 and coil 2. This may explain the 
additional, partial binding of mc29 to the variable peptides. In addition, it binds to most of the 
animal AA amyloids tested (see below).
4.2.4.4. mc1, mc4, mc13, mc29 and mc31
This series of monoclonal antibodies has been probed and exerted to establish a monoclonal 
micro-ELISA for quantification of SAA [42].
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5. On SAAs’ functions and their identification by blocking the 
invariant epitopes of SAA
5.1. The multifunctional SAA family
Various functions of SAA have been reported, including the systemic and local elevation of SAA 
in inflammations in an APR due to the systemic and local cytokine increase. SAA is involved 
in very many functions as being an opsonin of Gram-negative bacteria, a chemoattractant, an 
inducer of chemokines and cytokines, a stimulator of angiogenesis, important in cholesterol 
transport and a modulator in the migration of white blood cells. SAA acts concentration 
dependently on polymorphonuclear cells and the degradation of SAA (by matrix degradation 
enzymes?), which can release the AA 1–76 fragment and can thereby induce the fatal AA amy-
loidosis in humans and animals. Other fragments of SAA and other APPs may, in vivo, influ-
ence this still not understood complex network of the SAA family, which has been reviewed 
in [1, 2, 43, 44]. Here, some of these vital functions of SAA have been identified by blocking 
these functions by way of monoclonal AA/SAA antibodies. At the same time, the SAA binding 
motives have been localized at the surface of SAA (see Figure 5). Alternatively, these ligands 
for the SAA binding motives can, in part, be blocked with the respective synthetic peptides of 
SAA [44, 45].
5.2. HDL binding site
The HDL binding site of SAA was identified as the peptide aa 5–17 with the monoclonal mc1 
(see Section 4). The presumptive estimate by Turnell et al. [41] was aa 1–11.
5.3. Human neutrophils
Strong binding of isolated, acute-phase human SAA (and recombinant SAA2, not presented) 
were shown with human neutrophils [33] assuming the existence of an SAA receptor, which 
may have regulatory functions [1, 2]. The FMLP-induced oxidative burst of normal human 
neutrophils could be reduced, concentration dependently, by SAA at concentrations of 0.1 
μg/ml and 1.0 μg/ml. This inhibitory reduction of SAA could be blocked by the monoclonal 
antibody mc29 (see Table 1 and Figure 5), which binds to the synthetic peptide aa 28–40 of 
SAA, thus proving that this blocked area is responsible for this inhibitory effect of SAA [33]. 
This was the first time that a function of SAA was blocked by a monoclonal AA antibody. 
Moreover, at the same time, the responsible peptide of SAA was identified, which was the 
invariant peptide no. 7 of coil 2. The monoclonal antibody mc29 used probably also blocks 
the laminin-like domain (aa 29–33) and may also be participating partially with the RGD-like 
domain (aa 39–41). In addition, human neutrophils were exposed to full human APS at differ-
ent temperatures [34]. At 41°C, the inhibition of the oxidative burst was much stronger than 
at 37°C, indicating the role of SAA freed from HDL and in its active state (see Section 3.4; see 
Figures 3 and 4). However, when the acute-phase serum was preheated to 41°C for 15 min and 
assayed at 37°C, the SAA-containing serum did not return to the 37°C value, but stayed with 
the increased 41°C inhibiting effect at 37°C. This indicated an irreversible structural change 
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of SAA (or its fragments) during high fever, which is blocking SAA’s return to the reversible 
binding to HDL. (This febrile temperature that induced the aggregation of AA-antigenic pro-
teins has also been noticed in vitro and documented in Figure 3 at 38°C and 40°C). The possi-
bly unfavorable consequences of these aggregates in humans or animals are unknown today.
5.4. Anti-inflammatory potential of SAA on neutrophils
The anti-inflammatory potential of SAA on neutrophils [33] has been confirmed for SAA at 
reported serum concentrations [46]. Oxidative burst, migration and the neutrophil myeloper-
oxidase release were also inhibited. SAA peptides (aa 1–14, 15–101 and 83–104) also contrib-
uted to this inhibitory effect. However, at higher concentrations of more than 50 μg/ml, SAA 
was stimulating. In addition, O
2
 release was inhibited up to 0.1 μg/ml, but the O
2
 release was 
increased above that. Thus, SAA plays a dual role, it downregulates inflammatory processes 
in lower concentration, but, during the full APR, the action of SAA can be promoting.
5.5. SAA functions inhibited by synthetic peptides
SAA functions can be identified by SAA-generic antibodies [33, 34, 46] but they can also be 
blocked by synthetic peptides of SAA [45]. This was shown through the use of a 14mer synthetic 
peptide (aa 29–42) of SAA. This peptide inhibited the binding of T lymphocytes and mouse M4 
melanoma cells to adhesive glycoproteins of the extra cellular matrix. This SAA 14mer peptide 
contained the laminin-like (aa 29–33) and fibronectin-like (aa 13–15) domains of the extracellular 
matrix. Finally, by extending these data of the 14mer SAA peptide, by comparing to the binding 
of our generic antibodies mc21 and mc29, it is to be said that these antibodies bind to a similar 
peptide of SAA, which is the largest invariable peptide (no. 7 of coil 2) as shown in Figure 5.
5.6. Phagocytosis
Phagocytosis was examined on fixed bacteria by normal and stimulated blood monocytes at 
the SAA concentration that were inhibitory to human neutrophil activation [33]. There was no 
difference in phagocytosis in the presence or in the absence of SAA [47].
5.7. Platelets and binding motives similar to SAA
Human platelet adhesion was shown to immobilize SAA and the mechanism of binding was 
examined [35]. Among the many receptors on platelets, the receptors for laminin and fibronec-
tin were chosen to be examined because SAA has laminin-like and fibronectin-like motives in its 
sequence. Immobilized SAA binds platelets as do fibronectin and, to a lesser degree, fibrinogen. 
This binding of SAA to platelets was completely abolished by anti-SAA (mc29), which binds 
to the laminin-like motive on SAA (aa 29–33) that is part of the mc29-binding peptide. Also, 
a 29–42-containing peptide could inhibit the binding of platelets to SAA. In addition, an anti-
body against an integrin receptor also inhibited the binding as well the RGD-containing peptide 
GRGDSP. Also, the anti-SAA (mc29) did not inhibit the RGD-dependent binding motive to a 
significant extent, thus indicating that the overlap of two amino acids (aa 39–40) of the peptide 
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(see Figure 5) did not lead to an efficient paratope subsite of mc29 for the method applied. 
Finally, all controls were in line with the conclusion that SAA was binding to platelets via the 
laminin-like and fibronectin-like motives. Since the related binding motives are not chemically 
identical with laminin or fibronectin, they could have a lower affinity, which may be exerted dif-
ferently at lower concentrations as compared with higher concentrations, i.e., during the APR.
Thus, SAA may play a role in inhibiting and modulating platelet adhesion at vascular injury 
sites by sharing platelet receptors with other platelet-adhesive proteins. In addition, depend-
ing on the kind of disease, the window between bleeding and thrombosis may sometimes 
be very narrow; how can it be widened? Finally, systemic and local thrombosis are not rare, 
which are life-threatening sequels of many conditions. These are related to arteriosclerosis, 
heart conditions, nutrition-related ailments, deranged lipid metabolism, smoking and other 
drugs, cancer, injuries, bacterial infections and sepsis, mostly in a more advanced age as well 
as in cases of vascular injury. The role of platelets is central in these and many other diseases, 
and the concentration-dependent role of SAA and its antidotes (humanized monoclonals and 
others) in vivo needs to be explored and then further developed.
5.8. Presence of SAA in human cancer and other cells
Intracellular SAA of colon tissue with cancer of progressing stages of anaplasia was exam-
ined on formalin-fixed paraffin sections from 26 patients with colon cancer (after SAA plasma 
levels were shown by others to be elevated in carcinomas, assuming that the elevated SAA is 
of hepatic origin) [26]. SAA was detected immunohistochemically by using the monoclonal 
antibodies mc1 and mc29 (specificity, see Figure 5 and Table 1). On normal cells, no reaction 
or only traces were detected. However, stronger reactions were found in carcinoma cells. The 
staining intensity increased gradually from dysplasia to the stage of malignant neoplasia. The 
metastases also showed the presence of SAA, but weaker. In addition, cells, other than colon 
cells in these sections, also showed the presence of SAA as lymphoid cells of the intestinal wall, 
inflammatory cells, ganglion cells and endothelial cells. The presence of SAA has been con-
firmed by in situ hybridization and reverse transcriptase polymerase chain reaction (RT-PCR). 
The genes of SAA1 and SAA4 in the colon carcinomas were activated. Although the role of 
SAA in colon carcinoma is unknown, the close association of the increasing grade of malig-
nancy with the increased SAA synthesis may indicate a role of SAA in tumorigenesis. SAA 
can serve as an adhesive ligand for tumor-cell homing; it induces inflammation, which may be 
neoplastic. It also induces migration and can be involved in metastasis, or it can be inhibitory 
to attachment [26].
5.9. Protein SAA enhances plasminogen activation and may contribute to tumor 
spread
The colon carcinoma cell line HT-29 showed plasminogen activity (PA) enhanced by SAA 
measured with a chromogenic substrate. This activity could be inhibited using monoclonal 
antibodies against SAA (mc1 + mc29). The cell line also produced endogenous SAA1 by itself, 
which could be augmented by exogenous SAA and also by cytokines IL-1b and IL-6. This activ-
ity was also inhibited in part by the monoclonal antibodies against SAA [36]. The concomitant 
overexpression and co-localization of SAA and PA in colon cancer cells raises the possibility of 
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a functional relationship between these two systems. The authors suggest that SAA produced 
in the malignant tissue may contribute to increased matrix degeneration and tumor spread [36].
5.10. Gradual increase of SAA while progressing to malignancy in ovarian 
epithelial tumors
Increased levels of SAA were reported in a wide range of malignancies, as well as another 
unspecific tumor marker, with an increase in metastatic tumors and regression when therapy 
is successful [26]. Here, the presence of SAA in serum (with CRP and CA-123) and expressed 
locally in tissues was examined and compared with different stages of tumor growth. 
Compared were normal ovarian tissues, benign, borderline, carcinoma and metastatic tis-
sues of patients using immunohistochemistry with monoclonal antibodies against AA (mc1 
and mc29, see Table 1 and Figure 5) and in situ hybridization. In some patients (and in cell 
line OVCR-3), RT-PCR was applied, and SAA1 and SAA4 were detected. The result shows a 
continuous increase of SAA (CRP and CA-125) in serum during the gradual increase of the 
malignant nature of the ovarian tissue proliferation. In addition, and most important, the 
SAA expression in tissue increases, in the same manner, with a steep increase in the SAA-
synthesizing cells from the normal cells, without (or with only a trace of) SAA, over the bor-
derline tumors with weak expression to the maximal expression of the distinct carcinomas 
and metastases. Therefore, it is likely that the serum level of SAA in these malignancies may, 
in part, originate from the ovarian tumor itself.
The data show that the quantity of local intracellular expression of SAA correlates directly 
with the grade of malignancy of the ovarian epithelial neoplasias and runs in parallel with 
the serum value of SAA, CRP and CA-125. Therefore, SAA may have a role in ovarian tumor-
igenesis [27].
5.11. SAA in the female reproductive system
Ovarian reproduction includes a kind of inflammatory process [28]. Therefore, the cellular 
expression and localization of SAA in all stages of follicular development was examined in 
in vitro fertilization (IVF) patients applying nonradioactive in situ hybridization and immu-
nochemistry with the monoclonal anti-AA (mc1 and mc29) antibodies. In parallel, SAA of 
follicular fluids and SAA in serum were examined using micro-ELISA. Expression of SAA 
mRNA was found in all follicular cells (granulosa, thecal and luteal) of all stages of develop-
ment, from primordial, primary and secondary follicles to corpora lutea and even in oocytes.
The concentration of SAA in serum and in the matched follicular fluid was very closely associated 
(R2 = 0.80), although both values could vary considerably by a factor of ca. 30× for blood SAA and 
by 100× for the follicular fluid. In addition, elevated follicular SAA values have a strong correla-
tion with the patients’ body mass index. Values over 30 are associated with a reduced pregnancy 
rate. Taken together, SAA is locally produced by all follicular cells and is a constituent of the fol-
licular fluid. Therefore, it has a role in ovarian development and in the rate of pregnancy, which 
is reduced when SAA values are too high in overweight female patients with a BMI of over 30.
Finally, since human ovarian epithelial tissues reproduce SAA during reproduction (see above), 
the neoplastic degenerated cells in ovarian carcinoma continue their SAA synthesis [26].
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5.12. A role of SAA in the APR of murine septic inflammations
5.12.1. On the role of the APR and APPs in septic mice
In order to analyze the different steps necessary to overcome an infection by the hepatic APR, an 
experimental mouse model was applied and shown as an “anti-sepsis circle” (see Figure 6) [32]. 
Using polymicrobial sepsis induced by cecal ligation and puncture (CLP), the various actions 
begin with mice exposed to a bacterial overload that leads to the IL-6 induction, which is the 
dominant interleukin and major inductor of the APR. IL-6-deficient mice can still mount an APR, 
since IL-6 represents one member of a larger group of interleukins with redundant actions. The 
action of IL-6 is to initiate the intracellular signaling via the hepatic IL-6 receptor gp130 and 
further induction of STAT3, which is inevitable for developing the full hepatic APR in hepatic 
cells, including the synthesis of the dominant APP SAA. However, when mice with a deletion of 
gp130 or STAT3 are treated with CLP, the hepatic synthesis of SAA is not induced and these mice 
cannot mount an APR anymore and are thus defenseless, and mortality is greatly increased. The 
missing APR and the missing defense can be reversed by adding myeloid-derived suppressor 
cells (MDSCs), which are induced by a hepatic APR including SAA. SAA induces and activates 
the proliferation of bone marrow cells, which include MDSCs. These cells are accepted to be able 
to also act against the microbial infection. MDSCs are anti-inflammatory in cancer, cancer spread 
and metastases [27]. They home-in on different organs. In septic mice, they have been examined 
from spleen and increase their numbers when pg130 and STAT deficiency are overcome by an 
Figure 6. Closing the sepsis loop to the “anti-sepsis circle” schematically.
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injection of SAA, cxc1 (KC) or SAA/KC. MDSC can be regarded as a second anti-inflammatory 
wave induced by SAA and the other components of the APPs when the first wave of anti-inflam-
matory phagocytes is beginning to wane while becoming exhausted [1, 2, 27].
When very important functions of SAA (which need to be more clarified) are being blocked 
by the monoclonal antibodies mc4 and mc29 in CLP mice, the essential MDSCs cannot be 
produced to the necessary amount and function to cope with the bacterial load so that the 
mice become defenseless and display a significantly accelerated death rate. This unfavorable 
situation can be reverted by the injection of SAA, thereby resulting in the former defense with 
the proliferation of MDSCs, so that the mice survived like CLP-treated mice in this sepsis 
model [29, 30, 48]. The APP KC has a similar, but not identical, effect. When KC was added 
to SAA, the recovery from the CLP fate of mice with a murine SAA inactivated by antibodies 
may even be slightly improved, thus indicating that SAA, although the major and dominant 
APP, can be assisted by KC against the bacterial load.
This demonstrates a cooperative defense of SAA and KC [29]. Cooperation can also be 
expected from other APPs and constituents in the APP network, including from the greater 
SAA family. The AA antibodies mc4 and mc29 bind to invariant and therefore very important 
peptides of SAA as described in detail in Section 4.2, in Table 1 and Figure 5. With these 
antibodies, life-saving biological functions have been detected and their functions localized 
to invariant peptides of SAA. This approach could be extended to analyze all the invariant 
peptides of the SAA family. This can be regarded as a starting point for a possible therapy 
of a long list of such maladies as severe chronic inflammations and severe chronic infections 
including sepsis with (induced in vivo or recombinant) SAA isotypes (and their inhibitors as 
humanized generic SAA antibodies), and with other APPs and constituents of the network of 
the SAA family, which are able to fortify the “anti-sepsis circle” (Figure 6).
6. Some remarks
6.1. The septic loop became an “anti-sepsis circle” as a basis for further work
Some essential elements of the cooperative defense against the experimental multi-microbial 
infections became apparent as shown in Figure 6. The pathway from infection procedures 
passes, through IL-6, gp130 and STAT3, to the APR with the dominant SAA family and its net-
work. This loop has been closed to a circle through the action of at least the SAA1 that assisted 
in inducing the growth of the MDSCs in the bone marrow. These cells are also shown to be 
essential in fighting bacterial infection. However, when gp130 or SAA was not available in this 
model and the “circle” was interrupted, with fatal consequences, the addition of the missing 
agents restored the circle with its function [29]. It should be an important goal to examine the 
SAA isotypes in different inflammatory states and diseases in relation to febrile temperatures 
(Figures 3 and 4) and to analyze the functions of all 20 invariant peptides (Figure 5) and the 
epitopes of the AA/SAA antibodies (Table 1) in order fortify it.
It is also important to define the febrile temperatures by which the individual SAAs separate 
from HDL (proven in vitro, Figures 3 and 4) and get activated to execute their function. A 
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novel idea could be: therapeutical hypothermia below 37°C could inactivate SAA through 
binding to HDL, which can be called “hypothermic deactivation of SAA.” This option could 
be considered (after complying with the strict rules for a novel therapy) in severe inflamma-
tory states exemplified by sepsis, septic shock, genetic hyperthermia syndromes and simi-
lar diseases summarized in SIRS (systemic inflammatory response syndrome). Inversely, a 
 temperature-dependent conformational change of SAA at above 38°C causing  SAA release 
from HDL can induce a “hyper-thermic activation of SAA,” which could be beneficial for 
patients having clinical syndromes with body temperatures of 36°C and below.
6.2. Innate, humoral checkpoints for survival and application by industrial 
organizations
The presented view summarizes peptides of SAA that are decisive for innate humoral  func-
tions in different systems. This view can be applied to many possible possible inflammatory 
and infectious diseases, including sepsis. These SAA peptides provide a functional innate 
humoral “stop and go” mechanisms located on  SAA (“SAA checkpoints”) related to survival. 
Stop, with generic (humanized) AA/SAA monoclonal antibodies or equivalent agents, and go, 
with the bio-identical SAA preparations, including SAA isotypes or related peptides with spe-
cial SAA functions (Figure 5), which need to be further explored to find out their additional 
role in the SAA network. This examination can also be extended to other APPs.
6.3. European Patent EP No 2368564
Due to its novelty within the field of innate immunity and the possibly far-reaching impact in 
medicine, in particular, in inflammatory diseases including sepsis, these discoveries by three 
inventors were in agreement with the two other inventors patented by the author [49, 50].
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